PUBLICATIONS
REVIEWS
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig 1, Alejandro Forner 2, Jordi Rimola 3, Joana Ferrer-Fàbrega 4, Marta Burrel 5, Ángeles Garcia-Criado 3, Robin K Kelley 6, Peter R Galle 7, Vincenzo Mazzaferro 8, Riad Salem 9, Bruno Sangro 10, Amit G Singal 11, Arndt Vogel 12, Josep Fuster 13, Carmen Ayuso 14, Jordi Bruix 15
J Hepatol 2022;76(3):681-693
Pubmed abstract

Clinical presentation, diagnosis and staging of cholangiocarcinoma
Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A

Liver International 2019;10.1111/liv.14086
Pubmed abstract

Carbon-ion radiotherapy for HCC-A potential tool to fulfil an unmet gap in the treatment algorithms?
Da Fonseca LG, Forner A. Liv Int 2018;38:2132-2133
Pubmed abstract

Should Patients With NAFLD/NASH Be Surveyed for HCC?
Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C. Transplantation 2019;103:39-44
Pubmed abstract

New Systemic Treatments in Advanced Hepatocellular Carcinoma
 
Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M

Liver Transplantation 2018;doi: 10.1002/lt.25354
Pubmed abstract

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR

Cancer Treat Rev. 2018;68:16-24
Pubmed abstract

Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma
 
Darnell A, Belmonte E, Reig M, Brú C

Radiologia 2018;60:424-436
Pubmed abstract

New trials and results in systemic treatment of HCC
Reig M, da Fonseca LG, Faivre S

J Hepatology 2018;69:525-533
Pubmed abstract

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V J Hepatology 2018;:doi: 10.1016/j.jhep.2018.03.019
Pubmed abstract

Lenvatinib: can a non-inferiority trial change clinical practice?
Reig M, Bruix J

Lancet 2018;391:1123-1124
Pubmed abstract

Hepatocellular Carcinoma

Alejandro Forner, María Reig, Jordi Bruix

The Lancet 2018;10127:1301-1314
Pubmed abstract

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T

Cancer Treat Rev. ;10.1016/j.ctrv.2018.11.002
Pubmed abstract

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments

Reig M, Díaz-González Á, Bruix J Oncotarget 2017;8:106151-106152
Pubmed abstract

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

 
Reig M, Boix L, Mariño Z, Torres F, Forns X, Bruix J. Seminars in Liver Disease 2017;
Pubmed abstract

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J World J Gastroenterol 2017;
Pubmed abstract

Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches Sapisochin G, Bruix J

Nature Reviews. Gastroenterology and Hepatology 2017;14:203-217
Pubmed abstract

Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches
Sapisochin G., Bruix J.

Nat Rev Gastroenterol Hepatol 2017;:doi: 10.1038/nrgastro.2016.193
Pubmed abstract

Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH

Alejandro Forner
, María Reig, María Varela, Marta Burrel, Jaime Feliu, Javier Briceno, Javier Sastre, Luis Martí-Bonmati, Josep María Llovet, José Ignacio Bilbao, Bruno Sangro, Fernando Pardo, Carmen Ayuso, Concepció Bru, Josep Tabernero y Jordi Bruix

Medicina Clínica 2016;:doi: 10.1016/j.medcli.2016.01.028
Pubmed abstract

Evidence-based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

Bruix J
, Reig M, Sherman M.
Gastroenterology 2016;:doi: 10.1053/j.gastro.2015.12.041
Pubmed abstract

Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Nat Rev Clin Oncol. 2015;Aug;:12(8):436. doi: 10.1038/nrclinonc.2015.121.
Pubmed abstract

New molecular therapies for hepatocellular carcinoma. Torrecilla S, Llovet JM. Clin Res Hepatol Gastroenterol. 2015;Jul 20.:pii: S2210-7401(15)00151-5. doi: 10.1016/j.clinre.2015.06.016.
Pubmed abstract

Systemic Treatment: Expecting Further Success. Gazzola A, Reig M, Di Donato R, Bruix J. Dig Dis. 2015;;Jul 6.:33(4):590-7. doi: 10.1159/000375349.
Pubmed abstract

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Gastroenterology. 2015;Jun 20.:pii: S0016-5085(15)00869-0. doi: 10.1053/j.gastro.2015.05.061.
Pubmed abstract

Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Burak KW, Sherman M; Collaborators. Can J Gastroenterol Hepatol. 2015;May:29(4):178-84.
Pubmed abstract

Liver cancer: Approaching a personalized care. Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. J Hepatol. 2015;Apr:62(1S):S144-S156.
Pubmed abstract

Authors' response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. Bruix J, Gores G, Mazzaferro V. Gut. 2015;Mar:64(3):522.
Pubmed abstract

Biopsy for liver cancer: How to balance research needs with evidence-based clinical practice. Sherman M, Bruix J. Hepatology. 2015;Feb:61(2):433-7.
Pubmed abstract

Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Semin Liver Dis. 2014;Nov:34(4):444-55.
Pubmed abstract

Molecular profiling of liver tumors: classification and clinical translation for decision making. Pinyol R, Nault JC, Quetglas IM, Zucman-Rossi J, Llovet JM. Semin Liver Dis. 2014;Nov:34(4):363-75.
Pubmed abstract

Integration of genomic information in the clinical management of HCC. Quetglas IM, Moeini A, Pinyol R, Llovet JM. Best Pract Res Clin Gastroenterol. 2014;Oct:28(5):831-42
Pubmed abstract

Systemic treatment. Reig M, Gazzola A, Di Donato R, Bruix J. Best Pract Res Clin Gastroenterol. 2014;Oct;:28(5):921-35.
Pubmed abstract

Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Toso C, Mazzaferro V, Bruix J, Freeman R, Mentha G, Majno P. Am J Transplant. 2014;Oct;:14(10):2221-7.
Pubmed abstract

Treatment of intermediate-stage hepatocellular carcinoma. Forner A, Gilabert M, Bruix J, Raoul JL. Nat Rev Clin Oncol. 2014;Sep;:11(9):525-35.
Pubmed abstract

Usefulness of the molecular profile in the diagnosis, prognosis and treatment of hepatocellular carcinoma Bruix J. Gastroenterol Hepatol. 2014;Jul;:37 Suppl 2:81-9.
Pubmed abstract

LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Mitchell DG, Bruix J, Sherman M, Sirlin CB. Hepatology. 2014;Jul 12.
Pubmed abstract

Treatment of hepatocellular carcinoma. Liccioni A, Reig M, Bruix J. Dig Dis. 2014;:32(5):554-63.
Pubmed abstract

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. J Hepatol. 2014;Jun;:60(6):1268-89.
Pubmed abstract

Hepatocellular carcinoma: genome-scale metabolic models for hepatocellular carcinoma. Pinyol R, Llovet JM. Nat Rev Gastroenterol Hepatol. 2014;Jun;:11(6):336-7.
Pubmed abstract

Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. Villanueva A, Llovet JM. Nat Rev Clin Oncol. 2014 ;Feb;:11(2):73-4.
Pubmed abstract

Hepatocellular carcinoma: clinical frontiers and perspectives.

Bruix J, Gores GJ, Mazzaferro V.

Gut. 2014;Feb 14.
Pubmed abstract

Consensus report of the Fifth International Forum for Liver MRI.

Zech CJ, Bartolozzi C, Bioulac-Sage P, Chow PK, Forner A, Grazioli L, Huppertz A, Laumonier H, Min Lee J, Murakami T, Ricke J, Sirlin CB.

AJR Am J Roentgenol. 2013;Jul;:201(1):97-107.
Pubmed abstract

The size of the problem: clinical algorithms. Forner A, Bruix J Dig Dis. 2013;31(1):95-103.
Pubmed abstract

Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. Villanueva A. Journal of Hepatology 2013;Mar 30
Pubmed abstract

Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Villanueva A, Hernandez-Gea V, Llovet JM. Nat Rev Gastroenterol Hepatol 2013;Jan
Pubmed abstract

New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. Radiology 2013;266:376-382
Pubmed abstract

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J. Cancer. 2012;48:599-641.
Pubmed abstract

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012;56:908-943.

Download PDF

Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Abdo AA, Hassanain M, Aljumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, Almuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J. Ann Saudi Med 2012;32:174-199.
Pubmed abstract

Hepatocellular Carcinoma. Forner A, Llovet JM, Bruix J. Lancet 2012;379:1245-1255.
Pubmed abstract

Management of hepatocellular carcinoma. Rodriguez de Lope C, Tremosini S, Forner A, Reig M, Bruix J. J Hepatol. 2012;56 :75-87
Pubmed abstract

Gene signatures in the management of hepatocellular carcinoma. Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. Semin Oncol. 2012;Aug
Pubmed abstract

Clinical decision making and research in hepatocellular carcinoma: pivotal role of Imaging techniques. J Brix, M Reig, J Rimola, A Forner, M Burrel, R Vilana, C Ayuso. Hepatology 2011;54:2238-2244.
Pubmed abstract

Management of hepatocellular carcinoma: an update. J Bruix, M Sherman. Hepatology 2011;53:1020-1022.
Pubmed abstract
Download PDF

The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. A Hatzakis, S. Wait, J Bruix, M. Buti, M. Carballo, M. Cavaleri, M. Colombo, E Delarocque-Astagneau, G Dusheiko, G Esmat, R Esteban, D Goldberg, C Gore, AS Lok, M Manns, P Marcellin, G Papatheodoridis, A Peterle, D Prati, N Piorkowsky, M Rizzetto, F Roudot-Thoraval, V Soriano, HC Thomas, M Thursz, D Valla, P van Damme, IK Veldhuijzen, H Wedemeyer, L Wiessing, AR Zanetti, HL Janssen. J. Viral Hepat. 2011;18 :1-16
Pubmed abstract

What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation? Olthoff KM, Forner A, Hübscher S, Fung J. Liver Transpl. 2011;Oct
Pubmed abstract

Targeted therapies for hepatocellular carcinoma. Villanueva A, Llovet JM. Gastroenterology 2011;May
Pubmed abstract

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Cancer Treat Rev. 2011;May
Pubmed abstract

Signaling pathways in hepatocellular carcinoma. Sia D, Villanueva A. Oncology 2011;81
Pubmed abstract

Molecular pathogenesis of hepatocellular carcinoma Cornellà H, Alsinet C, Villanueva A. Alcohol Clin Exp Res. 2011;May
Pubmed abstract